MyMedR

Displaying all 5 publications

Abstract:

Sort:

Fulltext Titanium Dioxide/Polyvinyl Alcohol/Cork Nanocomposite: A Floating Photocatalyst for the Degradation of Methylene Blue under Irradiation of a Visible Light Source

Mohamad Idris NH, Rajakumar J, Cheong KY, Kennedy BJ, Ohno T, Yamakata A, et al.

ACS Omega, 2021 Jun 08;6(22):14493-14503.
PMID: 34124472 DOI: 10.1021/acsomega.1c01458

Photocatalytic degradation by the titanium dioxide (TiO2) photocatalyst attracts tremendous interest due to its promising strategy to eliminate pollutants from wastewater. The floating photocatalysts are explored as potential candidates for practical wastewater treatment applications that could overcome the drawbacks posed by the suspended TiO2 photocatalysis system. The problem occurs when the powdered TiO2 applied directly into the treated solution will form a slurry, making its reuse become a difficult step after treatment. In this study, the immobilization of titanium dioxide nanoparticles (TiO2 NPs) on the floating substrate (cork) employing polyvinyl alcohol (PVA) as a binder to anchor TiO2 NPs on the surface of the cork was carried out. Characterizations such as Fourier transformer infrared, X-ray diffraction (XRD), ultraviolet-visible spectroscopy (UV-vis), zeta potential, photoluminescence spectroscopy, femtosecond to millisecond time-resolved visible to mid-IR absorption spectroscopy, ion chromatography, and scanning electron microscopy-energy-dispersive X-ray spectroscopy (SEM-EDX) analyses were employed. XRD analysis revealed the formation of anatase-phase TiO2 NPs. The results demonstrated that the crystallite size was 9.36 nm. The band gap energy of TiO2 NPs was determined as 3.0 eV. PL analysis verified that TiO2 NPs possessed a slower recombination rate of electron-hole pairs as compared to anatase TiO2. The result was attributed by the behavior of photogenerated charge carriers on TiO2 NPs, which existed as shallowly trapped electrons that could survive longer than a few milliseconds in this study. Furthermore, SEM-EDX analysis indicated that TiO2 NPs were well distributed on the surface of the cork. At the optimal mole ratio of TiO2/PVA (1:8), the TiO2/PVA/cork floating photocatalyst degraded at 98.43% of methylene blue (MB) under a visible light source which performed better than under sunlight irradiation (77.09% of MB removal) for 120 min. Besides, the mineralization result has measured the presence of sulfate anions after photocatalytic activities, which achieved 86.13% (under a visible light source) and 65.34% (under sunlight). The superior photodegradation performance for MB was mainly controlled by the reactive oxygen species of the superoxide radical (•O2 -). The degradation kinetics of MB followed the first-order kinetics. Meanwhile, the Langmuir isotherm model was fitted for the adsorption isotherm. The floating photocatalyst presented good reusability, resulting in 78.13% of MB removal efficiency even after five cycles. Our TiO2/PVA/cork floating photocatalyst fabrication and high photocatalytic performance are potentially used in wastewater treatment, especially under visible light irradiation.
Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia

Wakatsuki M, Kato S, Ohno T, Banu PA, Hoang NC, Yadamsuren E, et al.

Int J Radiat Oncol Biol Phys, 2019 09 01;105(1):183-189.
PMID: 31125594 DOI: 10.1016/j.ijrobp.2019.04.039

PURPOSE: This multi-institutional observational study conducted among 11 countries in East and Southeast Asia aimed to assess the clinical outcomes of prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin for patients with locally advanced cervical cancer.
METHODS AND MATERIALS: Between October 2007 and May 2016, 106 patients with untreated squamous cell carcinoma of the cervix were enrolled in the present study. Radiation therapy consisted of pelvic irradiation (total dose, 50 Gy in 25 fractions including central shielding), prophylactic paraortic regional irradiation (36-40 Gy in 20 fractions), and either high- or low-dose-rate intracavitary brachytherapy (ICBT) according to institutional practice. The planned point A dose was 21 to 28 Gy in 3 to 4 fractions for high-dose-rate ICBT and 40 to 41 Gy in 1 to 2 fractions for low-dose-rate ICBT. Five cycles of weekly cisplatin (40 mg/m2) were administered during the radiation therapy course.
RESULTS: A total of 106 patients were enrolled. Of these, 9 had major protocol violations and 2 did not receive treatment because of worsened general condition. Thus, 95 patients were evaluable. The median follow-up was 56 months. Of the 95 patients, 76 (80%) received 4 or 5 cycles of chemotherapy. Acute grade 3 leukopenia was observed in 20 of the patients (21%), and late grade 3 gastrointestinal toxicity was observed in 3%. The 2-year local control, progression-free survival, and overall survival rate for all patients were 96%, 78%, and 90%, respectively.
CONCLUSIONS: The results indicated that prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin is feasible and effective for patients with locally advanced cervical cancer in East and Southeast Asia.
Fulltext Radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for N2-3 nasopharyngeal cancer: a multicenter trial of the Forum for Nuclear Cooperation in Asia

Ohno T, Thinh DH, Kato S, Devi CR, Tung NT, Thephamongkhol K, et al.

J Radiat Res, 2013 May;54(3):467-73.
PMID: 23192700 DOI: 10.1093/jrr/rrs115

The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for the treatment of N2-3 nasopharyngeal cancer (NPC) in Asian countries, especially regions of South and Southeast Asian countries where NPC is endemic. Between 2005 and 2009, 121 patients with NPC (T1-4 N2-3 M0) were registered from Vietnam, Malaysia, Indonesia, Thailand, The Philippines, China and Bangladesh. Patients were treated with 2D radiotherapy concurrently with weekly cisplatin (30 mg/m (2)), followed by adjuvant chemotherapy, consisting of cisplatin (80 mg/m(2) on Day 1) and fluorouracil (800 mg/m(2) on Days 1-5) for 3 cycles. Of the 121 patients, 56 patients (46%) required interruption of RT. The reasons for interruption of RT were acute non-hematological toxicities such as mucositis, pain and dermatitis in 35 patients, hematological toxicities in 11 patients, machine break-down in 3 patients, poor general condition in 2 patients, and others in 8 patients. Of the patients, 93% completed at least 4 cycles of weekly cisplatin during radiotherapy, and 82% completed at least 2 cycles of adjuvant chemotherapy. With a median follow-up time of 46 months for the surviving 77 patients, the 3-year locoregional control, distant metastasis-free survival and overall survival rates were 89%, 74% and 66%, respectively. No treatment-related deaths occurred. Grade 3-4 toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of the patients, respectively. In conclusion, further improvement in survival and locoregional control is necessary, although our regimen showed acceptable toxicities.
Fulltext Concurrent chemoradiotherapy for T3-4 and N0-1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia

Ohno T, Wakatsuki M, Thinh DH, Tung NT, Erawati D, Supriana N, et al.

J Radiat Res, 2016 Jan;57(1):44-9.
PMID: 26254458 DOI: 10.1093/jrr/rrv046

The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3-4 and N0-1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3-4 N0-1 M0, World Health Organization Type 2-3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m(2)). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3-4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis-free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes.
Fulltext Preliminary survey of 3D image-guided brachytherapy for cervical cancer at representative hospitals in Asian countries

Okonogi N, Wakatsuki M, Mizuno H, Fukuda S, Cao J, Kodrat H, et al.

J Radiat Res, 2020 Jul 06;61(4):608-615.
PMID: 32367130 DOI: 10.1093/jrr/rraa025

3D image-guided brachytherapy (3D-IGBT) has become a standard therapy for cervical cancer. However, the use of 3D-IGBT is limited in East and Southeast Asia. This study aimed to clarify the current usage patterns of 3D-IGBT for cervical cancer in East and Southeast Asia. A questionnaire-based survey was performed in 11 countries within the framework of the Forum for Nuclear Cooperation in Asia. The questionnaire collected the treatment information of patients with cervical cancer who underwent 3D-IGBT. The cumulative external beam radiotherapy and 3D-IGBT doses were summarized and normalized to a biological equivalent dose of 2 Gy per fraction (EQD2) using a linear-quadratic model. Of the 11 institutions representing the participating countries, six (55%) responded to the questionnaire. Overall, data of 36 patients were collected from the six institutions. Twenty-one patients underwent whole-pelvic irradiation and 15 underwent whole-pelvic irradiation with central shielding. Patients received a median of four treatment sessions of 3D-IGBT (range, 2-6). All 3D-IGBT sessions were computed tomography (CT)-based and not magnetic resonance image-based. The median doses to the high-risk clinical target volume D90, bladder D2cc, rectum D2cc and sigmoid colon D2cc were 80.9 Gy EQD2 (range, 58.9-105.9), 77.7 Gy EQD2 (range, 56.9-99.1), 68.0 Gy EQD2 (range, 48.6-90.7) and 62.0 Gy EQD2 (range, 39.6-83.7), respectively. This study elucidated the current patterns of 3D-IGBT for the treatment of cervical cancer in East and Southeast Asia. The results indicate the feasibility of observational studies of CT-based 3D-IGBT for cervical cancer in these countries.